Abstract 1116P
Background
Achieving a CR with ICI or with TT is associated with long-term survival in advanced melanoma pts. This is a retrospective study of the characteristics and long-term outcome of complete responders to ICI or TT.
Methods
Clinical data were collected between October 2010 and July 2022. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Cox multivariate proportional hazard regression model was applied to analyze association between clinical characteristics and PFS.
Results
A CR was achieved by 197 pts after ICI (anti-PD-1+/-anti-CTLA-4) for 168 (85.3%) and TT (anti-BRAF+/-anti-MEK) for 26 (13.2%) pts respectively. Median follow-up (FU) was 72 months (mos) [range=8;132]. Median duration of treatment (tx) was 11.1 mos [IQR=5.9;19.3] with ICI and 19.4 mos [IQR=8.5;30.4] with TT. Median duration to achieve the 1st CR was 9 mos with ICI and 13.9 mos with TT. Median duration of response was not reached (NR) with ICI and 2.28 mos [95%CI=1.15;NA] with TT. Relapses occurred in 38 (22.6%) and 16 (61.5%) of pts respectively, meaning a significantly higher relapse risk with TT than with ICI (HR=2.58 [95%CI=1.23 ;5.43], p=0.012). Median PFS was NR with ICI and 2.97 mos [95%CI=2.65;NA] with TT. PFS rate at 72 mos was 73.3% with ICI [95%CI=65.84;81.67] and 33.9% with TT [95%CI=18.27;63.21]. Number of lines, LDH, BRAF/NRAS mutation status were not statistically associated with relapse. Relapse occurred during tx in 6 (16.2%) and 8 (53.3%) pts and after tx discontinuation in 31 (83.8%) and 7 (46.4%) pts with ICI and TT respectively. The brain was a site of relapse in 2.9 % and 19.2% of responders to ICI and TT respectively (p: 0.0046, Fisher exact test). Among relapsing pts, 23 pts were rechallenged with ICI and 5 with TT, a new CR occurring in 3 and 2 pts respectively. Median OS was NR in both groups. After a median FU of 72 mos, 87.1% [95%CI=81.38;93.40] pts and 64.6% [95%CI=45.23;92.31] were alive respectively.
Conclusions
In this real life long-term study of patients in CR, 6 year PFS rates were 73.3% with ICI vs 33.9% with TT and 87.2% vs 64.6 % were alive with ICI and TT respectively. Brain relapses were significantly more frequent in the TT responder group than with ICI.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Caroline Robert.
Funding
Has not received any funding.
Disclosure
C. Boutros: Financial Interests, Personal and Institutional, Advisory Board: BMS; Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor: MSD; Financial Interests, Personal, Other, conference fee: Pierre Fabre; Financial Interests, Personal, Other, conference fees: Viatris. E. Routier: Financial Interests, Personal and Institutional, Other, conference fees: BMS, Pierre Fabre; Financial Interests, Personal and Institutional, Other, conference fee: Novartis; Financial Interests, Personal and Institutional, Other, compensation: BMS, Pierre Fabre, Novartis. C. Robert: Financial Interests, Personal and Institutional, Advisory Role: BMS, Pierre Fabre, Novartis, MSD, Roche, Sanofi, AstraZeneca, Merck; Financial Interests, Personal and Institutional, Other, cofounder: Ribonexus. All other authors have declared no conflicts of interest.
Resources from the same session
1150P - Transforming growth factor-beta-1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma
Presenter: Bernardo Rapoport
Session: Poster session 13
1151P - Characteristics and treatment outcomes in cutaneous adnexal carcinomas
Presenter: Adam Rock
Session: Poster session 13
1152P - Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Presenter: Fernanda Costa Svedman
Session: Poster session 13
1153P - Incidence and characteristics of immunotherapy related adrenal insufficiency in a monocenter, pan-cancer cohort of 4314 patients
Presenter: Minke Lucas
Session: Poster session 13
1154P - Thromboembolic events in patients with melanoma receiving immune checkpoint inhibitors: Incidence and risk factors
Presenter: Daan van Dorst
Session: Poster session 13
1155P - Application of novel machine learning to predict immunotherapy related toxicities for metastatic melanoma patients from baseline 18F-FDG PET/CT scans
Presenter: Roslyn Francis
Session: Poster session 13
1156P - Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome
Presenter: Eva Ellebæk
Session: Poster session 13
1157P - Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival
Presenter: Rik Verheijden
Session: Poster session 13
1158P - Association of corticosteroid (CS) exposure with treatment failure in patients (pts) with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
Presenter: Ha Mo Linh Le
Session: Poster session 13
1159P - Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801
Presenter: Pablo Cerezuela-Fuentes
Session: Poster session 13